Distinct Th17 effector cytokines differentially promote microglial and blood-brain barrier inflammatory responses

Insights

Group A Streptococcus infections can lead to neuropsychiatric issues in children. Interleukin-17A (IL-17A) drives these effects by impacting brain cells and the blood-brain barrier (BBB), offering a potential therapeutic target.

Area of Science:

  • Neuroscience
  • Immunology
  • Microbiology

Background:

  • Group A Streptococcus (GAS) infections in children can cause post-infectious encephalitis, leading to neuropsychiatric sequelae.
  • Th17 lymphocytes migrating to the brain are implicated in microglial activation and blood-brain barrier (BBB) impairment following GAS infections.

Approach:

  • Utilized single-cell RNA sequencing and spatial transcriptomics to investigate endothelial cell (EC) and microglia responses to GAS.
  • Analyzed Th17-derived cytokines critical for these cellular responses in a mouse model.

Key Points:

  • GAS infection alters ECs by downregulating BBB genes and microglia by upregulating interferon-response, chemokine, and antigen-presentation genes.
  • Elevated microglial-derived chemokines were detected in patient sera.
  • Neutralizing interleukin-17A (IL-17A) partially restored BBB function and reduced microglial chemokine gene expression.

Conclusions:

  • Interleukin-17A (IL-17A) plays a critical role in the neuropsychiatric sequelae associated with GAS infections.
  • Targeting IL-17A presents a potential therapeutic strategy for treating these post-infectious neurological disorders.